$147,105 raised*
FIRST GOAL HIT (you can still invest)
$2.40
Share Price
$18.9M
Valuation
$240
Min. Investment
$147K
Prev. Raised
$142,105 raised*
FIRST GOAL HIT (you can still invest)
$2.40
Share Price
$18.9M
Valuation
$240
Min. Investment
$147K
Prev. Raised
The Scrub Industry's Dirty Little Secret
Antimicrobial Silver
Silver is only antimicrobial when wet. Unless the wearer is sweating, it's not active. It's great for the gym, not so much in the clinic.
Coated Fabric Technologies
Antimicrobial coatings/finishes are applied at the end of the manufacturing process, increasing the chance of it washing off.
The $94B Medical Uniform Market That's Primed for Innovation
"Antimicrobial" scrubs today use antiquated silver coatings that are ineffective at keeping healthcare professionals safe in the clinic. Meanwhile, hospitals are flooded with innvoations across medtech. It’s time for a tech-infused update to the industry’s standard scrubs.
The Rx: More Effective Copper Infused Technology
Ouragins uses the most advanced copper-based infusion technology, ThreadFusion, to create scrubs that kill 99% of germs like MRSA and Klebsiella. This makes Ouragins 4x more effective than the leading "antimicrobial" competitor.
The Rx: More Effective Copper Infused Technology
Ouragins uses the most advanced copper-based infusion technology, ThreadFusion, to create scrubs that kill 99% of germs like MRSA and Klebsiella. This makes Ouragins 4x more effective than the leading "antimicrobial" competitor.
Results Matter
That’s why all Ouragins scrubs are scientifically tested and proven via independent third-party laboratories.
In a head-to-head test with the leading competitor, our proprietary ThreadFusion technology reduced 99% S. aureus, while the leading competitor only got a 22% reduction.
A World’s First: Turning Customers into Shareholders
Garnering customer loyalty is crucial for all brands. That’s why Ouragins is rewarding our most valuable customers with stocks in the company, simply for shopping.
As the world’s first ownership economy brand, Ouragins is inviting our customers to be partners in the brand to foster greater customer loyalty, engagement, and advocacy while creating more equitable rewards for the consumers who help build the brand.
With thousands of scrub-wearers, Ouragins is revolutionizing what it means to be a customer first brand.
The Growing Scrubs Market
That's not your pulse on the rise, it's the scrubs market
That's not your pulse on the rise, it's the scrubs market
The Growing Scrubs Market
There are 20+ million healthcare workers in the US alone with the vast majority wearing scrubs.
The number of healthcare occupations is expected to rise by 16% through 2030 (US Bureau of Labor Statistics).
85% of medical professionals purchase their own scrubs, resulting in recession-proof, predictable demand.
66% of professionals surveyed own six or more sets of scrubs with 18% owning nine or more sets at one time.
Reasons to Invest
The Cleanest Scrubs
Powered by ThreadFusion technology, all Ouragins pieces are tested to kill 99% of germs like MRSA and Klebsiella for scrubs that are more effective.
Stocks for Scrubs
By giving our scrub-wearers the opportunity to earn stocks in the company by shopping, Ouragins is turning customers into partners that are more engaged and loyal.
Premium Designs
Crafted by LA's top designers, Ouragins scrubs are constructed to move seamlessly with our healthcare professionals, all throughout their shift.
Campaign Vitals
Shares Offered
Common
Regulation
Regulation CF
Price Per Share
$2.40
Target Raise
$1,200,000
Minimum Investment
$240
Funding Round
Seed
We've Done This Before
Partnered with Iron Chef Hugh Acheson
We've Done This Before
Our team has been developing antimicrobial products since 2017 and we were the driving force behind OURA, the massively popular direct-to-consumer brand. Our technologies and products are already worn by tens of thousands around the world. Now, we’re bringing the same technology to an industry that needs it most: Healthcare
Seen on Law & Order: SVU
AS SEEN IN
We've Done This Before
Our team has been developing antimicrobial products since 2017 and we were the driving force behind OURA, the massively popular direct-to-consumer brand. Our technologies and products are already worn by tens of thousands around the world. Now, we’re bringing the same technology to an industry that needs it most: Healthcare
AS SEEN IN
The Team Caring for Your Investment
Shaun Veran
CEO
Michael Won
CMO
Elaine
Yue
CPO
Selva Kulasingam
CTO
The Perks of Investing
Level 1
$2,500
- Receive a free pair of Ouragins compression socks
Level 2
$5,000
- Level 1 Perks
- Inclusion in Product Development Round Table
- Receive a free scrubs set
Level 3
$10,000
- Level 2 Perks
- Receive a free healthcare Profession Care Package
Level 4
$25,000
- Level 3 Perks
- Receive naming rights for a limited-edition scrub color
- Sit in on a design session
Level 5
$50,000
- Level 4 Perks
- Scrubs donation to a community clinic in your name
Level 6
$100,000
- Level 5 Perks
- Invitation to the Ouragins Major Investor Soiree for you and a guest
Level 7
$250,000
- Level 6 Perks
- Join us for a visit to our LA facilities and sit down with the executive team. Flights, dining, and accomodation for you and a guest for 2 nights
Level 8
$500,000
- Level 7 Perks
- Receive naming rights for an Ouragins product
- Join us at a product launch event. Flights, dining, and accomodation for you and a guest for 3 nights
Frequently Asked Questions
For Non-Accredited Investors (most fall into this category) the limitation on how much you can invest depends on your net worth and annual income.
If either your annual income or your net worth is less than $107,000, then during any 12-month period, you can invest up to the greater of either $2,200 or 5% of the greater of your annual income or net worth.
If both your annual income and your net worth are equal to or more than $107,000, then during any 12-month period, you can invest up to 10% of annual income or net worth, whichever is greater, but not to exceed $107,000.
- After you review the offering statement and information and decide you’d like to invest and how much, you complete the application with the requested information and electronically sign the documentation.
- Rialto Markets, the Broker Dealer, reviews the information for Anti-Money Laundering and Know Your Customer type reviews
- If you pass the review, Rialto initiates the funds via ACH or Credit Card (or you send the wire or check if applicable)
- If you don’t pass the review, Rialto or the Issuer will reach out to you to update information to clear you for the reviews or otherwise
- Once the funds have been cleared by the escrow agent (funds go directly there), Rialto will match your funds with your cleared application for investment, and issue you the stock by validating the subscription agreement and notifying the Transfer Agent to record your ownership on the Issuers capitalization table.
The timeline is generally 2 to 4 weeks but can always happen sooner. It all depends on the information you provide and if there are issues, how quickly we hear back from you.
- If we bump up against any “hits” on our reviews, we are required to clear each one of those potential conflicts to evidence there are no issues.
- If the information provided is not correct or is incomplete, we will need to reach out and get this corrected.
- Even though funds are initiated or you see them pending in your funding source, this does not mean they are in the escrow account for the offering. Based on the payment rails available in the US, these funds may not appear in escrow for 1-2 days and then they have to sit there for a few days until the escrow agent is satisfied there doesn’t appear to be any issues.
- Matching of payments to approved applications happens in batches, so while all ready to be closed, your application maybe in the next batch.
Rialto Markets LLC is the FINRA/SEC registered Broker Dealer who has been engaged by the Issuer to act as the Onboarding Agent for this offering.
- Rialto Markets LLC is NOT placing or selling these securities on behalf of the Issuer.
- Rialto Markets LLC is NOT soliciting this investment nor making any recommendations by collecting, reviewing and processing your application for investment.
- Rialto Markets LLC conducts Anti-Money Laundering, Identity and Bad Actor Disqualification reviews of the Issuer, and ensures they are a registered business in good standing.
- Rialto Markets LLC is NOT validating or approving the information provided by the Issuer or the Issuer itself.
- Contact information is provided for applicants to make inquiries and requests of Rialto Markets LLC regarding the general application process, the status of the application or general Reg CF regulation related information. Rialto Markets LLC may direct applicants to specific sections of the Offering Statement to locate information or answers to their inquiry but does not opine or provide guidance on Issuer related matters.
By investing in an Issuer’s Reg CF offering where Rialto Markets is the Broker Dealer Onboarding Agent, Rialto must ensure that you as the investor, do not breach the SEC’s limits on investing in Reg CF Offerings within a 12 month period. While it’s not a full-fledged brokerage account where we custody your holdings or recommend any investments, you will have an account at Rialto to track the investments made where Rialto was engaged as the Broker Dealer Onboarding Agent.
There is NO cost, charge or no annual fees etc. for this account whatsoever.
By investing in an Issuer’s Reg CF offering where Rialto Markets is the Broker Dealer Onboarding Agent, Rialto must ensure that you as the investor, do not breach the SEC’s limits on investing in Reg CF Offerings within a 12 month period. While it’s not a full-fledged brokerage account where we custody your holdings or recommend any investments, you will have an account at Rialto to track the investments made where Rialto was engaged as the Broker Dealer Onboarding Agent.
There is NO cost, charge or no annual fees etc. for this account whatsoever.
As you are buying a security regulated by the SEC, and as a Broker Dealer we are required by SEC regulations to reasonably ensure Anti-Money Laundering and Know Your Customer reviews are satisfied and that Permitted Investor Limits are not breached, we collect this information to perform the required reviews.
Rialto may share certain details of an applying/completed investor as listed on the subscription agreement, with the Transfer Agent and Escrow Agent if requested for valid purposes of processing an investment application.
Applying investors with questions about the company or its product or the offering should submit their questions in the Discussion section of the investment website. This is a public forum where valid questions will be displayed for all to view, with responses clearly tagged with who the response is from (i.e., the Issuer, Rialto Markets).
An accredited investor, in the context of a natural person, includes anyone who:
- earned income that exceeded $200,000 (or $300,000 together with a spouse or spousal equivalent) in each of the prior two years, and reasonably expects the same for the current year, OR
- has a net worth over $1 million, either alone or together with a spouse or spousal equivalent (excluding the value of the person’s primary residence), OR
- holds in good standing a Series 7, 65 or 82 license.
Any questions about the application, how to navigate it, what’s the process, etc. should be directed to Rialto Markets using the contact information provided at the bottom of the investment website.
Updates:
You're Invited! Join us at a Rialto Webinar
November 22, 2022
Ouragins CEO Shaun Veran will be speaking as a panelist in Rialto’s upcoming live webinar “Secrets of Success” on November 29, 2022 at 10:00 am Pacific Time. He will be joined by other experts in the field to discuss the growth of private equity crowdfunding and how it results in more innovative companies that can make an impactful change.
Be sure to register for the webinar to join the conversation.
Immunology Expert Joins Board
November 2, 2022
Our Scientific Advisory Board is growing. As a science-first company, we use a data driven perspective to create an impact for the healthcare professionals that we have as customers.
That’s why we are so excited to announce that Dr. Bryan Xie has joined us. Dr. Xie received his PhD in Immunology from Stanford Medicine where he worked on discovering novel biomarkers and developing. ell therapies. With a collective decade of experience in research spanning academia and industry and in consulting and working at biotech startups, he brings with him an insight into the challenges and processes it takes to translate impactful innovations into the clinic.
We're Featured on KingsCrowd!
October 19, 2022
Watch the Ouragins Investor Webinars
October 14, 2022
Did you miss the investor webinars? You can view the recordings on our site. Learn all about the market opportunity, the revolutionary ThreadFusion technology, and how Ouragins is disrupting the scrubs industry. Check them out and feel free to let us know if you have any questions about the investment opportunity!
Infectious Diseases Expert Joins Board
October 5, 2022
At Ouragins, we take a scientific approach to everything that we do. Our scrubs are heavily tested and validated by independent laboratories and our Scientific Advisory Board is a key driver in the innovations that we make in this space.
We are extremely excited to announce that our Scientific Advisory Board is growing. Joining us in revolutionizing the scrubs industry with her expertise in infectious diseases is Dr. Ravina Kullar.
Dr. Ravina Kullar is an Infectious Diseases global expert and epidemiologist, who has spent 15 years researching in the infectious diseases space and has published over 50 peer-reviewed papers. She has been invited to provide 3 TED talks focused on the impact of antimicrobial resistance (AMR), sharing her own personal patient stories and providing action items that everyone can implement to be a part of the solution of infectious disease outbreaks.
Hear All About Our Technology
September 23, 2022
We are revolutionizing the scrubs industry with advanced antimicrobial technologies embedded within our scrubs.
Interested in learning more about this ground-breaking technology? We will be having a webinar taking a deep dive into the ThreadFusion technology embedded in every set of scrubs. This ground-breaking technology has been shown to be > 4x more effective than the leading competitor.
CEO Shaun Veran will be walking you through our secret sauce in an exclusive, LIVE webinar and investor Q&A session.
Be sure to sign up today and join us on October 11, 2022 at 2:00 PM Pacific Time. See you there!
Commitment Update
September 15, 2022
Total commitments are 9 investors for $142,105, including $100,008 investment from a separate Reg D offering with the same terms, conducted independently from Rialto Markets LLC.
Ourgains is in the news
September 13, 2022
Have you heard? Ouragins is getting featured in the press. We’ve gotten hits in International Business Times and Medical Daily?
Check them out to see the ways that Ouragins is transforming the scrubs industry with unique antimicrobial technologies and customer loyalty programs:
This Scrubs Brand is Revolutionizing Brand Loyalty
How to Prevent Germs With These Innovative Medical Scrubs
You're Invited to a Webinar with CEO Shaun Veran
September 1, 2022
We are on a mission to bring out proprietary antimicrobial technology to the areas that need it most. Curious to learn more?
Shaun Veran, Ouragins CEO, will be hosting an exclusive, LIVE investor Q&A webinar where we will share some amazing updates surrounding our company.
There is less than a week left to register so sign up today, and join us on September 7, 2022 at 2:00 PM Pacific Time (US and Canada).
Dont’ forget to bring those burning questions – a portion of this event will be dedicated to answering them! The Ouragins Executive team is looking forward to see you all in virtual attendance.
You're Invited to a Webinar with CEO Shaun Veran
September 1, 2022
We are on a mission to bring out proprietary antimicrobial technology to the areas that need it most. Curious to learn more?
Shaun Veran, Ouragins CEO, will be hosting an exclusive, LIVE investor Q&A webinar where we will share some amazing updates surrounding our company.
There is less than a week left to register so sign up today, and join us on September 7, 2022 at 2:00 PM Pacific Time (US and Canada).
Dont’ forget to bring those burning questions – a portion of this event will be dedicated to answering them! The Ouragins Executive team is looking forward to see you all in virtual attendance.
Discussion:
We are on a mission to bring out proprietary antimicrobial technology to the areas that need it most. Curious to learn more?
Shaun Veran, Ouragins CEO, will be hosting an exclusive, LIVE investor Q&A webinar where we will share some amazing updates surrounding our company.
There is less than a week left to register so sign up today, and join us on September 7, 2022 at 2:00 PM Pacific Time (US and Canada).
Dont’ forget to bring those burning questions – a portion of this event will be dedicated to answering them! The Ouragins Executive team is looking forward to see you all in virtual attendance.
You’re Invited to a Webinar with CEO Shaun Veran!
We are on a mission to bring our proprietary antimicrobial technology to the areas that need it most. Curious to learn more?
Shaun Veran, Ouragins CEO, will be hosting an exclusive, LIVE investor Q&A webinar where we will share some amazing updates surrounding our company.
There is less than a week left to register so sign up today, and join us on September 7th, 2022 at 2:00 PM Pacific Time (US and Canada).
Don’t forget to bring those burning questions – a portion of this event will be dedicated to answering them! The Ouragins executive team is looking forward to seeing you all in virtual attendance.